Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 50
- Profitability 75
- Business Quality 60
- Balance Sheet 40
- Cash Flow 45
Why this rating?
Health 56/100 — Acceptable
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Amneal Pharmaceuticals, Inc. (AMRX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Amneal Pharmaceuticals, Inc. 56/100 (Acceptable) due to solid business quality, steady revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Stretched
- Valuation Attractive
Financial highlights
Valuation
- P/E 35.52
- Forward P/E 14.69
- EV/Revenue 2.67
Profitability
- Revenue Growth 9.9%
- Gross Margin 39.8%
- Operating Margin 18.3%
- Net Margin 5.0%
- ROE 613.0%
Financial strength
- Cash $131.41M
- Debt $2.79B
- Net Cash $-2.66B
- Free Cash Flow $225.63M
- Current Ratio 2.21
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$9.06 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$73.56 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Neurocrine Biosciences, Inc. Drug Manufacturers - Specialty & Generic NBIX$155.13 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Lantheus Holdings, Inc. Drug Manufacturers - Specialty & Generic LNTH$100.44 70 Health 70 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$12.43 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$45.49 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Hims & Hers Health, Inc. Drug Manufacturers - Specialty & Generic HIMS$28.17 61 Health 61 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Supernus Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic SUPN$42.43 60 Health 60 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Amneal Pharmaceuticals, Inc. (AMRX).